68.95
price up icon2.04%   1.38
after-market After Hours: 68.79 -0.16 -0.23%
loading
Astrazeneca PLC stock is traded at $68.95, with a volume of 7.15M. It is up +2.04% in the last 24 hours and up +4.01% over the past month. AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, Symbicort Turbuhaler, and Tudorza Pressair for respiratory diseases; Fluenz FluMist/Tetra Quadrivalen and Synagis3 for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, and Vimovo4 for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. AstraZeneca PLC has a strategic partnership with Bicycle Therapeutics; and with Biothera Pharmaceuticals, Inc. to evaluate cancer related drugs, as well as has a collaboration agreement with Innate Pharma S.A. for oncology development. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC has clinical collaboration with Immunomedics, Inc. for the development of Imfinzi(R) and sacituzumab govitecan combination therapy, to include second-line metastatic non-small cell lung cancer. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
See More
Previous Close:
$67.57
Open:
$66.44
24h Volume:
7.15M
Relative Volume:
1.26
Market Cap:
$223.51B
Revenue:
$54.98B
Net Income/Loss:
$7.77B
P/E Ratio:
27.69
EPS:
2.49
Net Cash Flow:
$9.14B
1W Performance:
-4.36%
1M Performance:
+4.01%
6M Performance:
+5.77%
1Y Performance:
-10.66%
1-Day Range:
Value
$66.37
$68.95
1-Week Range:
Value
$66.37
$72.69
52-Week Range:
Value
$61.24
$87.67

Astrazeneca PLC Stock (AZN) Company Profile

Name
Name
Astrazeneca PLC
Name
Phone
44 20 3749 5000
Name
Address
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
Name
Employee
61,100
Name
Twitter
@AstraZeneca
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
AZN's Discussions on Twitter

Compare AZN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Major icon
AZN
Astrazeneca PLC
68.95 223.51B 54.98B 7.77B 9.14B 2.49

Astrazeneca PLC Stock (AZN) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-25 Initiated Exane BNP Paribas Outperform
Feb-13-25 Upgrade UBS Neutral → Buy
Feb-12-25 Initiated Morgan Stanley Overweight
Nov-20-24 Upgrade UBS Sell → Neutral
Nov-06-24 Upgrade Deutsche Bank Sell → Hold
Sep-13-24 Downgrade Deutsche Bank Hold → Sell
May-30-24 Initiated Goldman Buy
Apr-16-24 Upgrade Deutsche Bank Sell → Hold
Feb-08-24 Downgrade Deutsche Bank Hold → Sell
Jan-23-24 Initiated Morgan Stanley Overweight
Jan-16-24 Resumed UBS Sell
Jan-03-24 Downgrade Jefferies Buy → Hold
Dec-18-23 Initiated HSBC Securities Buy
Sep-25-23 Upgrade Jefferies Hold → Buy
Jul-14-23 Initiated HSBC Securities Buy
Jul-12-23 Upgrade UBS Neutral → Buy
Jul-05-23 Downgrade Deutsche Bank Buy → Hold
Apr-11-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-05-23 Initiated BMO Capital Markets Outperform
Sep-15-22 Downgrade Credit Suisse Outperform → Neutral
Sep-07-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Aug-29-22 Upgrade Argus Hold → Buy
Jun-14-22 Downgrade UBS Buy → Neutral
Feb-11-22 Upgrade DZ Bank Sell → Hold
Dec-07-21 Downgrade Jefferies Buy → Hold
Aug-12-21 Resumed JP Morgan Overweight
Apr-12-21 Downgrade Argus Buy → Hold
Mar-16-21 Upgrade Jefferies Hold → Buy
Feb-25-21 Upgrade UBS Neutral → Buy
Jan-15-21 Initiated Deutsche Bank Buy
Dec-07-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20 Upgrade UBS Sell → Neutral
Nov-11-20 Upgrade HSBC Securities Reduce → Hold
Sep-29-20 Initiated Berenberg Buy
Nov-22-19 Initiated SVB Leerink Outperform
Oct-25-19 Upgrade Liberum Hold → Buy
Apr-02-19 Downgrade UBS Neutral → Sell
Feb-05-19 Initiated Exane BNP Paribas Outperform
Jan-25-19 Upgrade Shore Capital Hold → Buy
Dec-11-18 Resumed Jefferies Hold
Oct-09-18 Initiated Guggenheim Buy
Aug-16-18 Downgrade Jefferies Buy → Hold
Mar-19-18 Upgrade Jefferies Hold → Buy
Feb-06-18 Reiterated Leerink Partners Mkt Perform
Feb-05-18 Reiterated Bernstein Outperform
Jan-18-18 Reiterated Leerink Partners Mkt Perform
Dec-29-17 Upgrade JP Morgan Neutral → Overweight
Oct-16-17 Upgrade Credit Suisse Neutral → Outperform
Sep-25-17 Upgrade Exane BNP Paribas Neutral → Outperform
Sep-22-17 Upgrade Bernstein Mkt Perform → Outperform
View All

Astrazeneca PLC Stock (AZN) Latest News

pulisher
02:26 AM

Potential Impact on AstraZeneca (AZN) from U.S. Pharma Pricing E - GuruFocus

02:26 AM
pulisher
11:56 AM

FTSE 100 LIVE: Stocks rise on US-China hopes, miners rally whilst AstraZeneca tumbles - Proactive Investors

11:56 AM
pulisher
11:39 AM

Executive Order Targets Drug Pricing: Impact on AstraZeneca (AZN - GuruFocus

11:39 AM
pulisher
10:11 AM

Eyes on Asia: NIH, Henlius, AstraZeneca - BioXconomy

10:11 AM
pulisher
07:58 AM

AstraZeneca (AZN) Gains UK Approval for Eco-Friendly Inhaler Pro - GuruFocus

07:58 AM
pulisher
07:47 AM

Why did the AstraZeneca share price just fall, and what should we do? - Fool UK

07:47 AM
pulisher
05:47 AM

AstraZeneca Loses Spot as UK’s Most Valuable Company to HSBC - Bloomberg.com

05:47 AM
pulisher
04:35 AM

GSK and Astrazeneca shares slump as Trump vows drug price cut - Yahoo

04:35 AM
pulisher
04:31 AM

Trump's new pharma policy sends GSK and AstraZeneca shares tumbling - business-live.co.uk

04:31 AM
pulisher
12:58 PM

AstraZeneca Obtains Approval for Low-carbon Inhaler from UK's MHRA - marketscreener.com

12:58 PM
pulisher
May 11, 2025

AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Cha - GuruFocus

May 11, 2025
pulisher
May 10, 2025

AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More InformationAZN - ACCESS Newswire

May 10, 2025
pulisher
May 09, 2025

AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Ca - GuruFocus

May 09, 2025
pulisher
May 09, 2025

AstraZeneca’s Imfinzi shows promise in bladder cancer trial By Investing.com - Investing.com UK

May 09, 2025
pulisher
May 09, 2025

AstraZeneca posts positive data for Imfinzi in bladder cancer (AZN:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 09, 2025

AstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment Brightens By Stocktwits - Investing.com India

May 09, 2025
pulisher
May 09, 2025

AstraZeneca (AZN) Trial Reveals Promising Results for Bladder Cancer Treatment | AZN Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

AstraZeneca Pharma India gets CDSCO approval for Enhertu for new breast cancer indication - Medical Dialogues

May 09, 2025
pulisher
May 09, 2025

AstraZeneca’s Imfinzi delays bladder cancer return in high-risk patients - Proactive Investors

May 09, 2025
pulisher
May 09, 2025

AstraZeneca’s Imfinzi improves disease-free survival in high-risk NMIBC - DirectorsTalk Interviews

May 09, 2025
pulisher
May 09, 2025

Astrazeneca Says Imfinzi Improved DFS In Early Bladder Cancer - marketscreener.com

May 09, 2025
pulisher
May 08, 2025

Trump, Starmer hail limited US-UK trade deal, but 10% duties remain - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

AstraZeneca (AZN) Sees Increased Bullish Option Activity | AZN S - GuruFocus

May 08, 2025
pulisher
May 08, 2025

US court shuts down AstraZeneca's challenge to Medicare drug price plan - Reuters

May 08, 2025
pulisher
May 08, 2025

Investors who Lost Money on AstraZeneca PLC (AZN) Should Contact Levi & Korsinsky About Pending Class ActionAZN - ACCESS Newswire

May 08, 2025
pulisher
May 08, 2025

High- and Low-Grade Serous Ovarian Cancer Market is Predicted to Grow at a CAGR of 7.9% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

May 08, 2025
pulisher
May 08, 2025

June 27th Options Now Available For AstraZeneca - Nasdaq

May 08, 2025
pulisher
May 08, 2025

AstraZeneca Loses Bid to Revive Drug Price Suit on Appeal (1) - Bloomberg Law News

May 08, 2025
pulisher
May 08, 2025

Britain set to strike first deal to cut Trump tariffs - marketscreener.com

May 08, 2025
pulisher
May 08, 2025

Does the GSK or AstraZeneca share price currently offer the best value? - MSN

May 08, 2025
pulisher
May 07, 2025

AstraZeneca (AZN) Achieves Key Milestone with Enhertu in Breast Cancer Trial - GuruFocus

May 07, 2025
pulisher
May 07, 2025

AstraZeneca marks Enhertu trial win in breast cancer (AZN) - Seeking Alpha

May 07, 2025
pulisher
May 07, 2025

AstraZeneca (LSE:AZN) Reports Positive Phase 3 Trial Results For Breast Cancer Treatment - Yahoo Finance

May 07, 2025
pulisher
May 07, 2025

AstraZeneca Says Enhertu Followed by THP Improved Pathologic Complete Response Rate in Breast Cancer Study - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment - insights.citeline.com

May 07, 2025
pulisher
May 07, 2025

ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Followed By THP Before Surgery Showed Statistically Significant And Clinically Meaningful Improvement In Pathologic Complete Response In High-Risk HER2-Positive Early-Stage Breast Cancer In DESTINY- - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

AstraZeneca (AZN) Sees Positive Results in DESTINY-Breast11 Trial | AZN Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief - Proactive Investors

May 07, 2025
pulisher
May 07, 2025

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model - Benzinga

May 07, 2025
pulisher
May 07, 2025

Multiple System Atrophy (MSA) Market Research 2025-2035 - GlobeNewswire Inc.

May 07, 2025
pulisher
May 07, 2025

AstraZeneca and GSK Share Price Slide as Markets React to Vinay Prasad’s FDA Appointment - paginasiete.bo

May 07, 2025
pulisher
May 07, 2025

AstraZeneca plc (LON: AZN) Shares Fall 2.2% in Early Morning Trading - paginasiete.bo

May 07, 2025
pulisher
May 07, 2025

REGAstraZeneca PLCEnhertu improved pCR in early-stage breast cancer - TradingView

May 07, 2025
pulisher
May 06, 2025

AstraZeneca (AZN): Impact of FDA's New Inspection Strategy on Fo - GuruFocus

May 06, 2025
pulisher
May 06, 2025

AstraZeneca unveils new factory as part of multibillion-dollar investment in US manufacturing - Yahoo Finance

May 06, 2025
pulisher
May 06, 2025

AstraZeneca unveils $300M Rockville investment, a boost for MoCo amid federal cuts - The Business Journals

May 06, 2025
pulisher
May 06, 2025

Berenberg: AstraZeneca, Eli Lilly Among Pharmaceutical Companies Set to Gain from US 'Pill Penalty' Update - marketscreener.com

May 06, 2025
pulisher
May 06, 2025

AstraZeneca's (AZN) Calquence Gains EU Approval for Mantle Cell Lymphoma Treatment | AZN Stock News - GuruFocus

May 06, 2025
pulisher
May 06, 2025

AstraZeneca's Calquence gets Europe approval for MCL - Sharecast.com

May 06, 2025
pulisher
May 06, 2025

AstraZeneca Plc Calquence combo approved in EU for first-line MCL - DirectorsTalk Interviews

May 06, 2025
pulisher
May 06, 2025

AstraZeneca's Calquence Regimen Wins EU Approval for Mantle Cell Lymphoma - marketscreener.com

May 06, 2025

Astrazeneca PLC Stock (AZN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
Cap:     |  Volume (24h):